1st Counsel – Lifestyle
Author:
RenovoRx, Inc.
RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP™ Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting
April 23, 2026
Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx’s TAMP™ Therapy Platform Presented at 2026 SIR Annual Scientific Meeting
April 14, 2026
RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath® Device for Targeted, Local Drug-Delivery via the Vasa Vasorum
April 8, 2026
RenovoRx Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026
April 1, 2026
RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update
March 30, 2026
RenovoRx Announces Key Phase III Milestone: TIGeR-PaC Trial Surpasses 100 Randomized Patients as Study Nears Completion of Enrollment
March 26, 2026
RenovoRx Announces Closing of Oversubscribed $10 Million at Market Private Placement
March 23, 2026
RenovoRx to Host Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Conference Call on March 30th at 4:30 p.m. ET
March 20, 2026
RenovoRx Announces $10 Million at Market Private Placement
March 18, 2026